The Effect of Proton Pump Inhibition on Palpitations

Status Completed

Clinical Trial Summary

Feeling of palpitations with no clear arrhythmia is frequently encountered in clinical practice. The majority of these patients have documented sinus rhythm even while having symptoms. Gastrointestinal association with such symptoms was first described by Ludwig von Roemheld (1871-1938).The investigators thought to investigate the effect of proton pump inhibition in patients with feeling of palpitations but no clear cause.

Clinical Trial Description

One hundred and fifty patients with palpitations and no clear cause for their symptoms will be randomized to receive either proton pump inhibitor (PPI) (lanzoprazole 30 mg) or placebo for one month. At base line they will be investigated to rule out arrhythmia by documenting normal heart rate (less than 110 beat per minute) or ECG showing normal sinus rhythm or mild sinus tachycardia (Less than 110 per minute) during symptoms. Obvious causes such as anxiety due to a stressful event or organic causes such anemia or thyroid disorders should be also ruled out.

Patient who agree to participate in the study will be asked to sign an informed consent. A baseline questionnaire with symptoms will be filled. They will then be randomized for treatment with either PPI or placebo once at night time. After 10 days of treatment they will be contacted and questioned regarding their symptoms. The two groups will be compared to see if there is any improvement of symptoms with treatment. ;

Study Design

Related Conditions & MeSH terms

Arrhythmia

Clinical Trial Details

NCT number	NCT03273634
Study type	Interventional
Source	Jordan Collaborating Cardiology Group
Contact
Status	Completed
Phase	Phase 4
Start date	May 20, 2017
Completion date	June 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05048602` - Drug-induced Brugada Syndrome Research Database
Completed	`NCT05053243` - Clinical Validation of the AliveCor Kardia 12L and 6L Devices	N/A
Completed	`NCT01913561` - The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection	N/A
Completed	`NCT01688648` - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft	N/A
Completed	`NCT01396226` - A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients	Phase 2
Terminated	`NCT00624520` - Mental Stress Reduction in Defibrillator Patients	Phase 3
Completed	`NCT00756886` - Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study	N/A
Terminated	`NCT00721149` - NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study	Phase 3
Completed	`NCT00510029` - Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously	Phase 1
Completed	`NCT00578617` - Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	N/A
Active, not recruiting	`NCT00135174` - Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study	N/A
Completed	`NCT00119847` - Electrophysiological Effects of Late PCI After MI	N/A
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Completed	`NCT00035490` - Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators	Phase 3
Completed	`NCT00004560` - Public Access Defibrillation (PAD) Community Trial	Phase 3
Completed	`NCT01076361` - Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study	N/A
Recruiting	`NCT00138931` - Genetics of Cardiovascular and Neuromuscular Disease
Completed	`NCT01076348` - Model 4965 Post-Approval Study
Completed	`NCT00622453` - Arrhythmias in Myotonic Muscular Dystrophy	N/A
Completed	`NCT00000531` - Antiarrhythmics Versus Implantable Defibrillators (AVID)	Phase 3